Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18758 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| SCHEMBL29359975 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| SCHEMBL29594563 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| SCHEMBL6916181 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| Hydrochloric Acid SCHEMBL1681545 | 0.80 | KDM4E (0.65) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| Terephthalic Acid SCHEMBL2846917 | 0.80 | TSHR (0.67) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| Bicarbonate SCHEMBL6557215 | 0.80 | KDM4E (0.65) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| SCHEMBL20942846 | 0.80 | KDM4E (0.65) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| Bromide SCHEMBL8758652 | 0.80 | KDM4E (0.65) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| Hydrochloric Acid SCHEMBL945629 | 0.80 | KDM4E (0.65) | KDM4EALDH1A1HPGDENPP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554505-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | claimed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | claimed |
| CN-1319590-A | 2,2,6,6, diethyl-dimethy-1-alkoxy-piperidine compound and 1-oxide | CIBA SC HOLDING AG (CH) | 2001-10-31 | — | — | CN | claimed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024042007-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| US-11673888-B2 | Bicyclic compounds as ATX inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-114920911-A | Method for producing polyisothianaphthene-based conductive polymer | 昭和电工株式会社 | 2022-08-19 | — | — | CN | disclosed |
| CN-110121516-B | Method for producing polyisothianaphthene-based conductive polymer | 昭和电工株式会社 | 2022-07-01 | — | — | CN | disclosed |
| US-11183340-B2 | Method for manufacturing solid electrolytic capacitor | SHOWA DENKO K.K. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-11136432-B2 | Method for producing polyisothianaphthene-based electroconductive polymer | SHOWA DENKO K.K. (JP) | 2021-10-05 | — | — | US | disclosed |
| EP-2217068-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2073804-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008135524-A2 | SUBSTITUTED ANTHRANILAMIDES AND ANALOGUES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008135526-A1 | CARBOXYLIC ACID AMIDES AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| EP-0901373-A4 | Alpha v Beta 3 ANTAGONISTS | MERCK & CO INC (US) | 1999-07-07 | — | — | EP | disclosed |
| EP-0901373-A1 | Alpha v Beta 3 ANTAGONISTS | Merck & Co., Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997037655-A1 | αvβ3 ANTAGONISTS | MERCK & CO., INC. (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | KDM4E 916/4885ALDH1A1 1943/4885HPGD 980/4885 |
| US-11673888-B2 | Bicyclic compounds as ATX inhibitors | ATXN2, ATXN2L, ATXN10 | KDM4E 1665/4885ALDH1A1 3458/4885HPGD 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.